Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SeaStar Medical Holding ( (ICU) ) has provided an update.
On July 2, 2025, SeaStar Medical Holding Corporation announced that it has regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement, ensuring its continued listing on the Nasdaq Capital Market. This compliance allows the company to focus on commercializing its QUELIMMUNE therapy and advancing its clinical development programs, including the NEUTRALIZE-AKI pivotal trial for adult patients with acute kidney injury, which could significantly impact its market positioning and stakeholder value.
The most recent analyst rating on (ICU) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on SeaStar Medical Holding stock, see the ICU Stock Forecast page.
Spark’s Take on ICU Stock
According to Spark, TipRanks’ AI Analyst, ICU is a Underperform.
SeaStar Medical Holding faces significant financial challenges, with negative equity and reliance on external financing posing risks to its financial health. Technical indicators show bearish momentum, and valuation metrics highlight ongoing losses, contributing to a low overall stock score.
To see Spark’s full report on ICU stock, click here.
More about SeaStar Medical Holding
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The company’s first commercial product, QUELIMMUNE, is FDA-approved for treating acute kidney injury (AKI) in critically ill pediatric patients. SeaStar Medical is also conducting a pivotal trial of its Selective Cytopheretic Device (SCD) therapy in adult patients with AKI.
Average Trading Volume: 5,379,384
Technical Sentiment Signal: Sell
Current Market Cap: $7.83M
For an in-depth examination of ICU stock, go to TipRanks’ Overview page.